Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed attachment file name title grouped question UIN question first answered answering member label
tabling member	label

Search

993833

	registered interest
	date	23/10/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what steps they are taking to reduce any disparity in access to rare disease medicines in England compared with economically similar countries in Europe.
	tabling member printed	Viscount Waverley
	uin	HL10966
	answer	answer is ministerial correction date of answer 06/11/2018 answer text <p>With the aim of improving the lives of all those affected by a rare disease, the United Kingdom Government published <em>The UK Strategy for Rare Diseases</em> in 2013, a high-level framework containing 51 commitments which sets out a seven-year strategic vision from 2013-2020. A copy of the Strategy is attached. The Government is committed to implementing the Strategy’s commitments and has, in January 2018, published two implementation plans setting out its actions for England. Copies of the Department’s <em>The UK Strategy for Rare Diseases: Rare Diseases implementation plan for England</em> and NHS England’s <em>Implementation Plan for the UK Strategy for Rare Diseases</em> are attached.</p><p>The Government has not made any assessment of differences in access to medicines for the treatment of rare diseases or on the available number of treatments between England, the devolved administrations and economically similar countries in Europe.</p><p>With regard to the Government’s assessment of the sustainability of the National Institute for Health and Care Excellence’s (NICE) appraisal process for rare disease medicines that do not meet the highly specialised technology criteria, patients with rare diseases in England benefit from the same NHS Constitution right to clinically and cost-effective medicines as patients with more common conditions. NICE has recommended a number of medicines for the treatment of rare diseases through its technology appraisal and highly specialised technology evaluation programmes which are now routinely available to National Health Service patients in line with NICE’s recommendations.</p> answering member printed Lord O'Shaughnessy attachment 1 file name UK_Strategy_for_Rare_Diseases.pdf title The UK Strategy for Rare Diseases 2 file name UK_strategy_for_rare_diseases_-_implementation_plan_for_England.pdf title UK Strategy for Rare Diseases Implementation Plan 3 file name NHSE implementation-plan-uk-strategy-for-rare-diseases.pdf title NHS England Rare Diseases Implementation Plan grouped question UIN HL10965 HL10967 HL10968 question first answered 06/11/2018 13:06:10 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1744 label Biography information for Viscount Waverley

993834

	registered interest
	date	23/10/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of how many treatments for rare diseases are available in Scotland that are unavailable in England.
	tabling member printed	Viscount Waverley
	uin	HL10967
	answer	answer is ministerial correction date of answer 06/11/2018 answer text <p>With the aim of improving the lives of all those affected by a rare disease, the United Kingdom Government published <em>The UK Strategy for Rare Diseases</em> in 2013, a high-level framework containing 51 commitments which sets out a seven-year strategic vision from 2013-2020. A copy of the Strategy is attached. The Government is committed to implementing the Strategy’s commitments and has, in January 2018, published two implementation plans setting out its actions for England. Copies of the Department’s <em>The UK Strategy for Rare Diseases: Rare Diseases implementation plan for England</em> and NHS England’s <em>Implementation Plan for the UK Strategy for Rare Diseases</em> are attached.</p><p>The Government has not made any assessment of differences in access to medicines for the treatment of rare diseases or on the available number of treatments between England, the devolved administrations and economically similar countries in Europe.</p><p>With regard to the Government’s assessment of the sustainability of the National Institute for Health and Care Excellence’s (NICE) appraisal process for rare disease medicines that do not meet the highly specialised technology criteria, patients with rare diseases in England benefit from the same NHS Constitution right to clinically and cost-effective medicines as patients with more common conditions. NICE has recommended a number of medicines for the treatment of rare diseases through its technology appraisal and highly specialised technology evaluation programmes which are now routinely available to National Health Service patients in line with NICE’s recommendations.</p> answering member printed Lord O'Shaughnessy attachment 1 file name UK_Strategy_for_Rare_Diseases.pdf title The UK Strategy for Rare Diseases 2 file name UK_strategy_for_rare_diseases_-_implementation_plan_for_England.pdf title UK Strategy for Rare Diseases Implementation Plan 3 file name NHSE implementation-plan-uk-strategy-for-rare-diseases.pdf title NHS England Rare Diseases Implementation Plan grouped question UIN HL10965 HL10966 HL10968 question first answered 06/11/2018 13:06:10 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1744 label Biography information for Viscount Waverley

993835

	registered interest
	date	23/10/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the sustainability of the NICE appraisal process for rare disease medicines that do not meet the highly specialised technology criteria.
	tabling member printed	Viscount Waverley
	uin	HL10968
	answer	answer is ministerial correction date of answer 06/11/2018 answer text <p>With the aim of improving the lives of all those affected by a rare disease, the United Kingdom Government published <em>The UK Strategy for Rare Diseases</em> in 2013, a high-level framework containing 51 commitments which sets out a seven-year strategic vision from 2013-2020. A copy of the Strategy is attached. The Government is committed to implementing the Strategy’s commitments and has, in January 2018, published two implementation plans setting out its actions for England. Copies of the Department’s <em>The UK Strategy for Rare Diseases: Rare Diseases implementation plan for England</em> and NHS England’s <em>Implementation Plan for the UK Strategy for Rare Diseases</em> are attached.</p><p>The Government has not made any assessment of differences in access to medicines for the treatment of rare diseases or on the available number of treatments between England, the devolved administrations and economically similar countries in Europe.</p><p>With regard to the Government’s assessment of the sustainability of the National Institute for Health and Care Excellence’s (NICE) appraisal process for rare disease medicines that do not meet the highly specialised technology criteria, patients with rare diseases in England benefit from the same NHS Constitution right to clinically and cost-effective medicines as patients with more common conditions. NICE has recommended a number of medicines for the treatment of rare diseases through its technology appraisal and highly specialised technology evaluation programmes which are now routinely available to National Health Service patients in line with NICE’s recommendations.</p> answering member printed Lord O'Shaughnessy attachment 1 file name UK_Strategy_for_Rare_Diseases.pdf title The UK Strategy for Rare Diseases 2 file name UK_strategy_for_rare_diseases_-_implementation_plan_for_England.pdf title UK Strategy for Rare Diseases Implementation Plan 3 file name NHSE implementation-plan-uk-strategy-for-rare-diseases.pdf title NHS England Rare Diseases Implementation Plan grouped question UIN HL10965 HL10966 HL10967 question first answered 06/11/2018 13:06:10 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1744 label Biography information for Viscount Waverley

823232

	registered interest
	date	15/01/2018
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Israel: USA
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they have made any recent representations to the government of the United States concerning the application of the provisions of the Jerusalem Embassy Act 1995; and if so, what response they received.
	tabling member printed	Viscount Waverley
	uin	HL4723
	answer	answer is ministerial correction date of answer 29/01/2018 answer text <p>While we have not discussed the specific application of the provisions of the Jerusalem Embassy Act 1995 with the Government of the United States, the Prime Minister made clear in her statement of 6 December 2017 that the UK disagrees with the United States' plans to move its embassy to Jerusalem and recognise Jerusalem as the Israeli capital before a final status agreement. The Prime Minister reiterated our position when she spoke to President Trump in December 2017.</p> answering member printed Lord Ahmad of Wimbledon question first answered 29/01/2018 18:05:03 answering member 4210 label Biography information for Lord Ahmad of Wimbledon
	tabling member	1744 label Biography information for Viscount Waverley

823229

	registered interest
	date	15/01/2018
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Balfour Declaration
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of which of the aspirations contained in the Balfour Declaration have been fulfilled; and if not all, which ones they consider not to have been fulfilled, and why.
	tabling member printed	Viscount Waverley
	uin	HL4720
	answer	answer is ministerial correction date of answer 29/01/2018 answer text <p>While we are proud that the UK played a role in helping to make a Jewish homeland a reality, the Balfour Declaration remains unfinished business. That is why we are committed to ensuring that the whole of Balfour is fulfilled, through a two-state solution which provides security and justice for both Israelis and Palestinians. Our focus now is on encouraging the parties to take steps which bring them closer to peace.</p> answering member printed Lord Ahmad of Wimbledon question first answered 29/01/2018 18:02:02 answering member 4210 label Biography information for Lord Ahmad of Wimbledon
	tabling member	1744 label Biography information for Viscount Waverley

846709

	registered interest
	date	21/02/2018
	answering body	Department for Exiting the European Union
	answering dept id	203
	answering dept short name	Exiting the European Union
	answering dept sort name	Exiting the European Union
	hansard heading	European Union: English Language
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what representations they have made to seek to ensure that, after Brexit, English will be retained as an official language of the EU.
	tabling member printed	Viscount Waverley
	uin	HL5764
	answer	answer is ministerial correction date of answer 01/03/2018 answer text <p>While the UK will maintain an interest, any decision on official languages of the EU after the UK’s withdrawal will be one to be taken by the EU institutions and their Member States.</p> answering member printed Lord Callanan question first answered 01/03/2018 15:57:22 answering member 4336 label Biography information for Lord Callanan
	tabling member	1744 label Biography information for Viscount Waverley

675222

	registered interest
	date	18/01/2017
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Central America: EU External Relations
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government when Parliament will be asked to ratify the EU–Central America Association Agreement.
	tabling member printed	Viscount Waverley
	uin	HL4787
	answer	answer is ministerial correction date of answer 30/01/2017 answer text <p>We support the objectives of the EU-Central America Association Agreement and are considering when to put it to Parliament.</p> answering member printed Baroness Anelay of St Johns question first answered 30/01/2017 12:30:54 answering member 3474 label Biography information for Baroness Anelay of St Johns
	tabling member	1744 label Biography information for Viscount Waverley

750584

	registered interest
	date	11/07/2017
	answering body	Department for Exiting the European Union
	answering dept id	203
	answering dept short name	Exiting the European Union
	answering dept sort name	Exiting the European Union
	hansard heading	Solicitors: Training
	house id	2
	legislature	25277 pref label House of Lords
	question text	Her Majesty's Government whether they have given any consideration to the creation of a new supra-national dispute resolution mechanism relating to the enforcement of the rights of EU citizens living in the UK and UK citizens living in the the EU following Brexit.
	tabling member printed	Viscount Waverley
	uin	HL716
	answer	answer is ministerial correction date of answer 24/07/2017 answer text <p>We recognise that the large majority of ​international agreements involve some form of dispute resolution or enforcement mechanism​ and there are a range of models for dispute resolution mechanisms in international agreements. <br>​We have been clear that we will bring an end to the jurisdiction of the European Court of Justice in the United Kingdom. The dispute resolution mechanisms adopted as part of our future relationship with the EU will be a matter for negotiation.</p><p> </p> answering member printed Baroness Anelay of St Johns question first answered 24/07/2017 15:00:15 answering member 3474 label Biography information for Baroness Anelay of St Johns
	tabling member	1744 label Biography information for Viscount Waverley

919386

	registered interest
	date	07/06/2018
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Russia: Sanctions
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the potential effect of the counter-sanctions law, signed by the President of the Russian Federation on 4 June, on (1) UK–Russia relations, (2) UK–Russia trade, (3) UK investors in Russia, and (4) Russian investors in the UK.
	tabling member printed	Viscount Waverley
	uin	HL8464
	answer	answer is ministerial correction date of answer 19/06/2018 answer text <p>We have noted that President Putin signed the draft law on 4 June. It remains to be seen how the new law will be applied. We will continue to monitor the implementation of this new legislation closely, including any potential implications for UK companies.</p> answering member printed Lord Ahmad of Wimbledon question first answered 19/06/2018 10:44:29 answering member 4210 label Biography information for Lord Ahmad of Wimbledon
	tabling member	1744 label Biography information for Viscount Waverley

627569

	registered interest
	date	02/11/2016
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Iran: Bank Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether they have taken any action to prevent the Iranian Embassy in London from opening a UK bank account; and if so, why.
	tabling member printed	Viscount Waverley
	uin	HL2944
	answer	answer is ministerial correction date of answer 15/11/2016 answer text <p>We have not taken any action to prevent the Iranian Embassy in London from opening a UK bank account.</p> answering member printed Baroness Anelay of St Johns question first answered 15/11/2016 17:07:43 answering member 3474 label Biography information for Baroness Anelay of St Johns
	tabling member	1744 label Biography information for Viscount Waverley